Mojdeh S Kappus1, Andrew J Murphy, Sandra Abramowicz, Vusisizwe Ntonga, Carrie L Welch, Alan R Tall, Marit Westerterp. 1. From the Division of Molecular Medicine, Department of Medicine, Columbia University, New York, NY (M.S.K., A.J.M., S.A., V.N., C.L.W., A.R.T., M.W.); Department of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY (M.S.K.); and Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, The Netherlands (M.W.).
Abstract
OBJECTIVE: Liver X receptor (LXR) activators decrease atherosclerosis in mice. LXR activators (1) directly upregulate genes involved in reverse cholesterol transport and (2) exert anti-inflammatory effects mediated by transrepression of nuclear factor-κB target genes. We investigated whether myeloid cell deficiency of ATP-binding cassette transporters A1 and G1 (ABCA1/G1), principal targets of LXR that promote macrophage cholesterol efflux and initiate reverse cholesterol transport, would abolish the beneficial effects of LXR activation on atherosclerosis. APPROACH AND RESULTS: LXR activator T0901317 substantially reduced inflammatory gene expression in macrophages lacking ABCA1/G1. Ldlr(-/-) mice were transplanted with Abca1(-/-)Abcg1(-/-) or wild-type bone marrow (BM) and fed a Western-type diet for 6 weeks with or without T0901317 supplementation. Abca1/g1 BM deficiency increased atherosclerotic lesion complexity and inflammatory cell infiltration into the adventitia and myocardium. T0901317 markedly decreased lesion area, complexity, and inflammatory cell infiltration in the Abca1(-/-)Abcg1(-/-) BM-transplanted mice. To investigate whether this was because of macrophage Abca1/g1 deficiency, Ldlr(-/-) mice were transplanted with LysmCreAbca1(fl/fl)Abcg1(fl/fl) or Abca1(fl/fl)Abcg1(fl/fl) BM and fed Western-type diet with or without the more specific LXR agonist GW3965 for 12 weeks. GW3965 decreased lesion size in both groups, and the decrease was more prominent in the LysmCreAbca1(fl/fl)Abcg1(fl/fl) group. CONCLUSIONS: The results suggest that anti-inflammatory effects of LXR activators are of key importance to their antiatherosclerotic effects in vivo independent of cholesterol efflux pathways mediated by macrophage ABCA1/G1. This has implications for the development of LXR activators that lack adverse effects on lipogenic genes while maintaining the ability to transrepress inflammatory genes.
OBJECTIVE: Liver X receptor (LXR) activators decrease atherosclerosis in mice. LXR activators (1) directly upregulate genes involved in reverse cholesterol transport and (2) exert anti-inflammatory effects mediated by transrepression of nuclear factor-κB target genes. We investigated whether myeloid cell deficiency of ATP-binding cassette transporters A1 and G1 (ABCA1/G1), principal targets of LXR that promote macrophage cholesterol efflux and initiate reverse cholesterol transport, would abolish the beneficial effects of LXR activation on atherosclerosis. APPROACH AND RESULTS: LXR activator T0901317 substantially reduced inflammatory gene expression in macrophages lacking ABCA1/G1. Ldlr(-/-) mice were transplanted with Abca1(-/-)Abcg1(-/-) or wild-type bone marrow (BM) and fed a Western-type diet for 6 weeks with or without T0901317 supplementation. Abca1/g1 BM deficiency increased atherosclerotic lesion complexity and inflammatory cell infiltration into the adventitia and myocardium. T0901317 markedly decreased lesion area, complexity, and inflammatory cell infiltration in the Abca1(-/-)Abcg1(-/-) BM-transplanted mice. To investigate whether this was because of macrophage Abca1/g1 deficiency, Ldlr(-/-) mice were transplanted with LysmCreAbca1(fl/fl)Abcg1(fl/fl) or Abca1(fl/fl)Abcg1(fl/fl) BM and fed Western-type diet with or without the more specific LXR agonist GW3965 for 12 weeks. GW3965 decreased lesion size in both groups, and the decrease was more prominent in the LysmCreAbca1(fl/fl)Abcg1(fl/fl) group. CONCLUSIONS: The results suggest that anti-inflammatory effects of LXR activators are of key importance to their antiatherosclerotic effects in vivo independent of cholesterol efflux pathways mediated by macrophage ABCA1/G1. This has implications for the development of LXR activators that lack adverse effects on lipogenic genes while maintaining the ability to transrepress inflammatory genes.
Entities:
Keywords:
ATP-binding cassette transporters; atherosclerosis; inflammation; liver X receptor; macrophages
Authors: Annabel F Valledor; Li-Chung Hsu; Sumito Ogawa; Dominique Sawka-Verhelle; Michael Karin; Christopher K Glass Journal: Proc Natl Acad Sci U S A Date: 2004-12-15 Impact factor: 11.205
Authors: Eric D Bischoff; Chris L Daige; Mary Petrowski; Harry Dedman; Jennifer Pattison; Joseph Juliano; Andrew C Li; Ira G Schulman Journal: J Lipid Res Date: 2010-05 Impact factor: 5.922
Authors: Li Zhang; Karen Reue; Loren G Fong; Stephen G Young; Peter Tontonoz Journal: Arterioscler Thromb Vasc Biol Date: 2012-08-30 Impact factor: 8.311
Authors: Satoko Arai; John M Shelton; Mingyi Chen; Michelle N Bradley; Antonio Castrillo; Angie L Bookout; Puiying A Mak; Peter A Edwards; David J Mangelsdorf; Peter Tontonoz; Toru Miyazaki Journal: Cell Metab Date: 2005-03 Impact factor: 27.287
Authors: Nancy Levin; Eric D Bischoff; Chris L Daige; Diane Thomas; Calvin T Vu; Richard A Heyman; Rajendra K Tangirala; Ira G Schulman Journal: Arterioscler Thromb Vasc Biol Date: 2004-11-11 Impact factor: 8.311
Authors: Sebastian Zimmer; Alena Grebe; Siril S Bakke; Niklas Bode; Bente Halvorsen; Thomas Ulas; Mona Skjelland; Dominic De Nardo; Larisa I Labzin; Anja Kerksiek; Chris Hempel; Michael T Heneka; Victoria Hawxhurst; Michael L Fitzgerald; Jonel Trebicka; Ingemar Björkhem; Jan-Åke Gustafsson; Marit Westerterp; Alan R Tall; Samuel D Wright; Terje Espevik; Joachim L Schultze; Georg Nickenig; Dieter Lütjohann; Eicke Latz Journal: Sci Transl Med Date: 2016-04-06 Impact factor: 17.956
Authors: Kai Yin; Yong You; Vicki Swier; Lin Tang; Mohamed M Radwan; Amit N Pandya; Devendra K Agrawal Journal: Arterioscler Thromb Vasc Biol Date: 2015-09-17 Impact factor: 8.311